Please login to the form below

Not currently logged in

Cellerant appoints William Reed as VP clinical development

Will lead development of stem cell-based treatments for blood conditions and cancer

US biotech Cellerant Therapeutics has named Dr William Reed as VP, clinical development.

Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.

He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease.

Dr Reed was also an investigator at Blood Systems Research Institute in San Francisco and a medical director of the Human Islet and Cellular Transplantation Facility at University of California, San Francisco (UCSF).

Ram Mandalam, president and CEO of Cellerant, said:"His extensive experience in paediatric haematology/oncology and transfusion medicine will significantly benefit Cellerant in the development of CLT-008 for cord blood transplantation, leukaemia and acute radiation syndrome applications and the future clinical development of our cancer stem cell programme.”

15th February 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...